Improved survival associated with somatic PIK3CA mutations in copy‑number low endometrioid endometrial adenocarcinoma

Lin,Douglas I.

doi:10.3892/ol.2015.3702

Improved survival associated with somatic PIK3CA mutations in copy‑number low endometrioid endometrial adenocarcinoma

Authors:
- Douglas I. Lin
View Affiliations

Affiliations: Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Published online on: September 15, 2015 https://doi.org/10.3892/ol.2015.3702
Pages: 2743-2748
Copyright: © Lin . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The phosphoinositide‑3‑kinase (PI3K) signaling pathway has been implicated in the development of endometrioid endometrial adenocarcinoma (EEC). Recently, The Cancer Genome Atlas (TCGA) project stratified EEC into four molecular subgroups, with the majority of tumors falling into the copy‑number low‑EEC (CNL‑EEC) molecular subgroup. The aim of the present study was to investigate whether alterations of the PI3K pathway are associated with specific survival outcomes in patients with EEC. The clinical and genomic data of 307 patients with endometrioid‑type tumors were obtained from TCGA project, including 90 patients in the CNL‑EEC subgroup. Patients were evaluated in terms of survival and clinicopathological characteristics, as well as mutations in the PI3K catalytic subunit alpha (PIK3CA) gene and their effect on PIK3CA function. In CNL‑EEC subgroup patients, somatic PIK3CA mutations (48/90 cases) were associated with significantly improved overall survival compared with that of wild‑type PIK3CA (P=0.018). Furthermore, this improved survival was specific to the CNL‑EEC subgroup and was not observed in other TCGA molecular subgroups. The majority of CNL‑EEC cases were low‑stage (stage I) and low‑to‑intermediate grade (grades 1‑2) endometrioid tumors. There were no significant differences in age, stage, histology or International Federation of Gynecology and Obstetrics grade between PIK3CA‑mutated and non‑mutated patient groups (P>0.05). In addition, the majority of cases contained activating PIK3CA mutations. Overall, in the TCGA cohort, PIK3CA mutations had a favorable effect on the survival of patients with EEC, and this effect was dependent on tumoral molecular sub‑stratification. Future studies on larger independent cohorts with long term follow‑up are warranted to further analyze this association.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
3	Siegel RI, De Santis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
4	Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, et al: Cancer Genome Atlas Research Network: Integrated genomic characterization of endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI
5	Risinger JI, Hayes AK, Berchuck A and Barrett JC: PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 57:4736–4738. 1997.PubMed/NCBI
6	Oda K, Stokoe D, Taketani Y and McCormick F: High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65:10669–10673. 2005. View Article : Google Scholar : PubMed/NCBI
7	Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y, Sone K, Miyamoto Y, Hiraike H, Hiraike-Wada O, et al: The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer. 101:145–148. 2009. View Article : Google Scholar : PubMed/NCBI
8	Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M and Bell DW: PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res. 71:4061–4067. 2011. View Article : Google Scholar : PubMed/NCBI
9	Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ and Bell DW: A unique spectrum of somatic PIK3CA (p110α) mutations within primary endometrial carcinomas. Clin Cancer Res. 17:1331–1340. 2011. View Article : Google Scholar : PubMed/NCBI
10	Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, et al: High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 1:170–185. 2011. View Article : Google Scholar : PubMed/NCBI
11	Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, et al: Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 22:2120–2129. 2012. View Article : Google Scholar : PubMed/NCBI
12	Edge S, Byrd D, Compton C, et al: AJCC Cancer Staging. Manual (7th). (New York, NY). Springer. 2010.
13	Silverberg SG, Kurman RJ, Nogales F, et al: Tumors of the uterine corpus: Epithelial tumours and related conditions. Tumors of the Breast and Gynecologic Tract. Tavassoli FA and Devilee PL: (Lyon). IARC Press. 2182002.
14	Burke JE, Perisic O, Masson GR, Vadas O and Williams RL: Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc Natl Acad Sci USA. 109:15259–15264. 2012. View Article : Google Scholar : PubMed/NCBI
15	Gymnopoulos M, Elsliger MA and Vogt PK: Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA. 104:5569–5574. 2007. View Article : Google Scholar : PubMed/NCBI
16	Rios JJ, Paria N, Burns DK, Israel BA, Cornelia R, Wise CA and Ezaki M: Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. Hum Mol Genet. 22:444–451. 2013. View Article : Google Scholar : PubMed/NCBI
17	Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI
18	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:112013.
19	Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR, Nishihara R, Meyerhardt JA, et al: Prognostic role of PIK3CA mutation in colorectal cancer: Cohort study and literature review. Clin Cancer Res. 18:2257–2268. 2012. View Article : Google Scholar : PubMed/NCBI
20	Zhang L, Shi L, Zhao X, Wang Y and Yue W: PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma. Onco Targets Ther. 6:497–502. 2013.PubMed/NCBI
21	Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, et al: PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 15:5049–5059. 2009. View Article : Google Scholar : PubMed/NCBI
22	Shigaki H, Baba Y, Watanabe M, Murata A, Ishimoto T, Iwatsuki M, Iwagami S, Nosho K and Baba H: PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin Cancer Res. 19:2451–2459. 2013. View Article : Google Scholar : PubMed/NCBI
23	McIntyre JB, Nelson GS, Ghatage P, Morris D, Duggan MA, Lee CH, Doll CM and Köbel M: PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma. Gynecol Oncol. 132:188–193. 2014. View Article : Google Scholar : PubMed/NCBI
24	Catasus L, Gallardo A, Cuatrecasas M and Prat J: PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol. 21:131–139. 2008.PubMed/NCBI
25	Dong Y, Yang X, Wong O, Zhang X, Liang Y, Zhang Y, Wong W, Nong L, Liao Q and Li T: PIK3CA mutations in endometrial carcinomas in Chinese women: Phosphatidylinositol 3-kinase pathway alterations might be associated with favorable prognosis. Hum Pathol. 43:1197–1205. 2012. View Article : Google Scholar : PubMed/NCBI